Cetera Investment Advisers
CRDF icon

Cetera Investment Advisers’s Cardiff Oncology CRDF Stock Holding History

Cetera Investment Advisers’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-38,000
Closed -$101K – 3803
2024
Q3 		$101K Sell
38,000
-2,500
-6% -$5.91K ﹤0.01% 3536
2024
Q2 		$89.9K Buy
+40,500
New +$153K ﹤0.01% 3526

Other funds holding CRDF

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cetera Investment Advisers's CRDF Position: Q4 2024 in Review

Cetera Investment Advisers sold out of Cardiff Oncology (CRDF) in Q4 2024, closing a stake of 38,000 shares — an estimated $101K sold.

Cetera Investment Advisers first reported a position in CRDF in Q2 2024 and held it in 2 quarters. The position peaked at $101K in Q3 2024. 117 funds tracked by Wall St. Rank hold CRDF as of Q4 2024.

  • Cetera Investment Advisers reported no remaining Cardiff Oncology position as of Q4 2024 after selling out during the quarter.
  • Cetera Investment Advisers sold 38,000 Cardiff Oncology shares in Q4 2024, an estimated $101K.
  • Cetera Investment Advisers first reported a position in Cardiff Oncology in Q2 2024 and held it in 2 quarters.
  • Cetera Investment Advisers's Cardiff Oncology position peaked at $101K in Q3 2024.
  • 117 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2024.

Based on Cetera Investment Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.